Please refer to the full Prescribing Information for SHINGRIX for full details.

  • Refrigerate between 2º and 8ºC (36º and 46ºF). Protect vials from light. DO NOT FREEZE (discard if frozen)
  • Reconstitute and use immediately
  • Reconstituted vaccine is stable for 6 hours refrigerated between 2º and 8ºC (36º and 46ºF), and should be discarded after 6 hours. Do not freeze. Discard if the reconstituted vaccine has been frozen

Adjuvant Suspension Component Vial 1 of 2

1 Cleanse both vial stoppers. Using a sterile needle and sterile syringe, withdraw the entire contents of vial 1,  containing the adjuvant suspension component, by slightly tilting the vial. Sterile Needle Withdraw Contents of Vial

Adjuvant Suspension Component Vial 2 of 2

2 Slowly transfer entire contents of syringe into the lyophilized antigen component in vial 2. Syringe Transfer into Lyophilized Antigen Component Vial
3 Gently shake the vial to thoroughly mix contents until powder is completely dissolved. The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid. Vial Shake to Mix and Dissolve Powder

VZV=varicella zoster virus; gE=glycoprotein E.

4 After reconstitution, withdraw 0.5 mL from the vial containing the reconstituted vaccine and administer intramuscularly. Sterile Needle Withdraw 0.5 mL from Vial

Reconstituted Vaccine


  View reconstitution instructions for SHINGRIX.


SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Reference: Prescribing Information for SHINGRIX.

All trademarks are the property of their respective owners.

1004182R0 April 2018